News
Fredun Pharmaceuticals surges after Q1 PAT rises 94% YoY to Rs 13 crore
05-Aug-2026 | 14:44
Fredun Pharmaceuticals jumped 13.99% to Rs 1264.95 after the company's consolidated net profit increased by 94.1% to Rs 13.13 crore in Q1 FY27 from Rs 6.76 crore in Q1 FY26.
Revenue from operations rose by 90.7% year-on-year (YoY) to Rs 227.75 crore during the period under review.
Total expenses rose by 86.6% to Rs 206.79 crore in Q1 FY27 from Rs 110.81 crore in Q1 FY26. This was primarily due to higher raw material costs (up 97.6% YoY), higher depreciation charges (up 151.6% YoY) and higher other expenses (up 52.5% YoY).
Profit before tax in Q1 FY27 stood at Rs 20.55 crore, up 127.3% from Rs 9.04 crore in Q1 FY26.
Fredun Pharmaceuticals manufactures pharmaceutical formulations such as tablets, syrups, capsules, and ointments. The company's product basket includes multiple therapeutic classes such as anti-diabetics, anti-retroviral, anti-hypertensive etc.
Powered by Capital Market - Live News